Brief: Mithra Pharmaceuticals And Mayne Pharma Announce TGA Approval Of Nextstellis
29/11/2021 09:25
Nov 29 (Reuters) - Mithra Pharmaceuticals SA MITRA.BR :
* MAYNE PHARMA AND MITHRA ANNOUNCE TGA APPROVAL OF
NEXTSTELLIS®
ORAL CONTRACEPTIVE
* MAYNE PHARMA ANTICIPATES COMMERCIAL LAUNCH OF NEXTSTELLIS
BY
MID-2022 SUPPORTED BY HEALTHCARE PROFESSIONAL MARKET EDUCATION
FROM JANUARY 2022
* CONTAINING A NEW CHEMICAL ENTITY (NCE), NEXTSTELLIS WILL
RECEIVE
5 YEARS OF MARKET EXCLUSIVITY
Source text: https://bit.ly/3D9n7yU
Further company coverage: MITRA.BR
(Gdansk Newsroom)
((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Mithra Pharmaceuticals SA
See all newsBrief: Mithra Sells Estetra, Neuralis, Specific Assets To Gedeon Richter for EUR 175 Mln
Brief: Mithra Receives Additional EUR 2.5 Million To Advance Monetization
Brief: Mithra Secures Court Protection Measures To Advance Monetization Process
Brief: Mithra Pharmaceuticals Achieves LPR In Estetrol Skin Study
Brief: Mithra Applies To Liege Company Court For A "Transfer Under Judicial Supervision" For Mithra CDMO